Vancomycin vs Oritavancin: What the Research Compares

Vancomycin and oritavancin are both prescription antibacterial medicines used in hospital and infusion settings, and both belong to the glycopeptide family of cell wall active agents. This page summarises what the published literature reports when the two are placed side by side: where randomized head to head data exist, where they do not, how the two molecules are described mechanistically, and what reviews report about tolerability. It does not rank the two medicines, does not declare one preferable, and does not provide instructions for use. This page is for educational purposes only and is not medical advice; consult a licensed physician about any infection, medicine or treatment decision.

Where head to head randomized evidence exists

The clearest direct comparison between the two medicines comes from the skin infection setting. A 2015 review of oritavancin described two randomized, double blind, multicentre phase 3 trials, SOLO I and SOLO II, conducted in adults with acute bacterial skin and skin structure infections, in which oritavancin given as a single complete intravenous regimen was compared against intravenous vancomycin administered over several days (PMID 25661747). A separate 2015 review in Drugs reported that a single 1200 mg intravenous dose of oritavancin met noninferiority criteria against intravenous vancomycin dosed twice daily for 7 to 10 days in those trials, with early clinical response at 48 to 72 hours as the primary efficacy measure (PMID 26464319). A third 2015 review reached the same descriptive conclusion, reporting comparable efficacy between the single dose oritavancin regimen and the multi dose vancomycin comparator in acute bacterial skin and skin structure infections (PMID 25803197).

An important caveat applies to the passages above: the sources cited here are review articles that summarise the SOLO program, not the primary trial reports themselves. Readers who want the original randomized data, including enrolment numbers, confidence intervals and secondary endpoints, would need to consult the primary publications, which are outside the citation set used on this page.

Trial design as described in the cited reviews

The doses above are reproduced only as study design detail from the cited reviews. They describe what investigators administered inside a controlled trial and are not guidance for any individual.

Where no head to head randomized trial was identified

Outside acute bacterial skin and skin structure infections, the literature cited on this page contains no randomized trial that assigned patients to vancomycin versus oritavancin. For bloodstream infection, bone and joint infection, prosthetic joint infection and enterococcal disease, the two medicines appear in separate bodies of work with different designs, different endpoints and different levels of evidence. The comparison in those settings is therefore indirect, and the two evidence bases are summarised side by side rather than pooled.

Evidence base associated with vancomycin

• A 2019 review of antibiotic penetration into bone and joints covered glycopeptides among the agents assessed for distribution into bone and synovial tissue, a parameter relevant to osteoarticular infection (PMID 30772469).
• A 2023 narrative review of ampicillin resistant but vancomycin susceptible Enterococcus faecium bacteremia discussed vancomycin among the treatment options considered in that clinical scenario (PMID 37294450).
• A reference overview of glycopeptide antibiotics described vancomycin within its class, including mechanism, spectrum and monitoring considerations (PMID 31643291).

Evidence base associated with oritavancin

• A 2022 laboratory study reported synergy between oritavancin and fosfomycin against vancomycin resistant Enterococcus faecium in both in vitro and in vivo models (PMID 36289992).
• A 2022 study of Staphylococcus aureus biofilm infection reported that a persister targeting drug combination eradicated biofilm in the model used (PMID 36289936).
• A 2022 study reported that antimicrobial efficacy against antibiotic tolerant Staphylococcus aureus depended on the mechanism by which tolerance arose, a finding relevant to how glycopeptides and lipoglycopeptides perform against non growing populations (PMID 36551467).
• A 2020 case report described sequential oritavancin dosing in a prosthetic hip infection caused by Enterococcus faecalis with preservation of the prosthesis and without surgical manipulation of the joint (PMID 32983892). A single case report describes one patient and cannot establish comparative efficacy.

Class and mechanism as described in the literature

Vancomycin is the reference glycopeptide, and a class overview described glycopeptides as agents that bind the D alanyl D alanine terminus of peptidoglycan precursors and thereby block cell wall cross linking in Gram positive bacteria (PMID 31643291). Oritavancin is a semisynthetic lipoglycopeptide derived from that scaffold, and a 2022 review of semisynthetic glycopeptide development covering 2014 to 2022 described how lipophilic side chain modification added membrane directed activity to the original cell wall binding mechanism (PMID 35895325). A 2015 review of oritavancin similarly described multiple mechanisms of action, including inhibition of cell wall synthesis together with effects on the bacterial membrane (PMID 25803197).

Structural work has examined the two molecules alongside each other. A 2022 vibrational optical activity study characterised four antibiotic glycopeptides and lipoglycopeptides, vancomycin, oritavancin, dalbavancin and teicoplanin, and reported spectroscopic differences consistent with their distinct substituents and conformations (PMID 36506196).

Side by side summary

Regulatory status

Vancomycin is a long established prescription antibacterial medicine and is described in reference literature as the reference agent of the glycopeptide class (PMID 31643291). Oritavancin is a prescription antibacterial medicine approved for acute bacterial skin and skin structure infections caused by susceptible Gram positive organisms, and 2015 reviews described it in that approved indication as a single dose complete regimen (PMID 25661747, PMID 26464319). Both are administered under medical supervision, and every question about whether either is appropriate in a given case belongs with a prescribing clinician.

Adverse Events: What Studies Report

Reviews of the SOLO program reported that the single dose oritavancin regimen was generally well tolerated and that the adverse event profile observed was broadly similar in character to the vancomycin comparator arm, with gastrointestinal effects such as nausea and vomiting, headache and infusion related reactions among the events described (PMID 26464319). A further 2015 review described tolerability in the skin infection trials as acceptable and discussed the practical implications of a long half life agent, including the fact that an administered dose cannot be withdrawn once given (PMID 25803197). Reviews also noted that oritavancin can interfere with certain laboratory coagulation assays for a period after administration, which has implications for interpreting those results (PMID 25661747).

For vancomycin, the glycopeptide class overview described the recognised toxicity and monitoring considerations associated with the class, including renal and infusion related effects that shape how the medicine is administered and followed (PMID 31643291). The 2023 narrative review of enterococcal bacteremia also discussed the practical considerations that accompany prolonged glycopeptide therapy in that population (PMID 37294450).

How to read this comparison

1. Only one setting has direct randomized data. The comparison is anchored in acute bacterial skin and skin structure infections, where reviews reported noninferiority of a single oritavancin dose against multi day vancomycin (PMID 26464319).
2. Noninferiority is a statistical statement, not a ranking. The cited reviews described the result as comparable efficacy on the trial endpoint, not as superiority (PMID 25803197).
3. Laboratory and case data do not transfer across settings. Synergy in a vancomycin resistant enterococcus model (PMID 36289992) and a single prosthetic joint case report (PMID 32983892) describe findings in those specific models and patients only.
4. Tolerance and biofilm state matter in the models. One 2022 study reported that efficacy against tolerant Staphylococcus aureus varied with the underlying mechanism of tolerance (PMID 36551467).

Related reading

• Vancomycin overview
• Oritavancin overview

References

• Antibiotic penetration into bone and joints: An updated review (International Journal of Infectious Diseases, 2019)
• Glycopeptide Antibiotics (2012)
• Ampicillin-resistant and vancomycin-susceptible Enterococcus faecium bacteremia: a clinical narrative review (Expert Review of Anti-infective Therapy, 2023)
• Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections (Expert Review of Anti-infective Therapy, 2015)
• Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022 (ACS Infectious Diseases, 2022)
• Oritavancin for acute bacterial skin and skin structure infections (Expert Opinion on Pharmacotherapy, 2015)
• Vibrational Optical Activity Study of Four Antibiotic (Lipo)glycopeptides: Vancomycin, Oritavancin, Dalbavancin, and Teicoplanin (ACS Omega, 2022)
• In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium (Antibiotics, 2022)
• Eradication of Staphylococcus aureus Biofilm Infection by Persister Drug Combination (Antibiotics, 2022)
• Oritavancin: a review in acute bacterial skin and skin structure infections (Drugs, 2015)
• Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation (IDCases, 2020)
• Antimicrobial Efficacy against Antibiotic-Tolerant Staphylococcus aureus Depends on the Mechanism of Antibiotic Tolerance (Antibiotics, 2022)